Abstract:The EphB4 receptor tyrosine kinase together with its preferred ligand, ephrin-B2, regulates a variety of physiological and pathological processes, including tumor progression, pathological forms of angiogenesis, cardiomyocyte differentiation and bone remodeling. We previously reported the identification of TNYL-RAW, a 15 amino acid-long peptide that binds to the ephrin-binding pocked of EphB4 with low nanomolar affinity and inhibits ephrin-B2 binding. Although ephrin-B2 interacts promiscuously with all the EphB receptors, the TNYL-RAW peptide is remarkably selective and only binds to EphB4. Therefore, this peptide is a useful tool for studying the biological functions of EphB4 and for imaging EphB4-expressing tumors. Furthermore, TNYL-RAW could be useful for treating pathologies involving EphB4-ephrin-B2 interaction. However, the peptide has a very short half-life in cell culture and in the mouse blood circulation due to proteolytic degradation and clearance by the kidneys and reticuloendothelial system. To overcome these limitations, we have modified TNYL-RAW by fusion with the Fc portion of human IgG1, complexation with streptavidin or covalent coupling to a 40 KDa branched polyethylene glycol (PEG) polymer. These modified forms of TNYL-RAW all have greatly increased stability in cell culture, while retaining high binding affinity for EphB4. Furthermore, PEGylation most effectively increases peptide half-life in vivo. Consistent with increased stability, submicromolar concentrations of PEGylated TNYL-RAW effectively impair EphB4 activation by ephrin-B2 in cultured B16 melanoma cells as well as capillary-like tube formation and capillary sprouting in co-cultures of endothelial and epicardial mesothelial cells. Therefore, PEGylated TNYL-RAW may be useful for inhibiting pathological forms of angiogenesis through a novel mechanism involving disruption of EphB4-ephrin-B2 interactions between endothelial cells and supporting perivascular mesenchymal cells. Furthermore, the PEGylated peptide is suitable for other cell culture and in vivo applications requiring prolonged EphB4 receptor targeting.

Study on Pegylation of Antineoplasm Metastatic Poly-Beta Peptide

Effect of the Pegylation of Trimeric Β Peptide on It's Anti-metastasis Activity

The Influence of Β Peptide Dimmer Modified by Polyethylene Glycol on Anti-Metastasis Activity

Synthesis and Systematic Study on the Effect of Different PEG Units on Stability of PEGylated, Integrin-αvβ6-Specific A20FMDV2 Analogues in Rat Serum and Human Plasma

In Vivo Pharmacokinetics, Immunogenicity and Mechanism of PEGylated Antitumor Polypeptide

Studies of poly(ethylene glycol) modification of HM-3 polypeptides.

Modification of antimicrobial peptide with low molar mass poly(ethylene glycol).

Site-specific Modification of Anti-Angiogenesis Peptide HM-3 by Polyethylene Glycol Molecular Weight of 20 Kda.

Study on Tumor Targeting Ability of Neovessel-Targeted PEGylated Liposomes

Biophysical and Biological Characterization of PEGylated Recombinant Human Endostatin

PROGRESS RESEARCH OF IN PEG MODIFIED DRUGS

Poly(ethyl Ethylene Phosphate): Overcoming the "polyethylene Glycol Dilemma" for Cancer Immunotherapy and Mrna Vaccination.

Pegylation Potentiates The Effectiveness Of An Antagonistic Peptide That Targets The Ephb4 Receptor With Nanomolar Affinity

Impact of PEGylation on biodistribution and tumor accumulation of Lipid-Mu peptide-DNA

Quantitatively fine-tuning the physicochemical and biological properties of peptidic polymers through monodisperse PEGylation.

Peptide Decoration of Nanovehicles to Achieve Active Targeting and Pathology-Responsive Cellular Uptake for Bone Metastasis Chemotherapy.

PEGylation Strategy for Improving the Pharmacokinetic and Antitumoral Activity of the IL-2 No-alpha Mutein

Poly(l-glutamic acid)-cisplatin nanoformulations with detachable PEGylation for prolonged circulation half-life and enhanced cell internalization

Branched PEG-modification: A new strategy for nanocarriers to evade of the accelerated blood clearance phenomenon and enhance anti-tumor efficacy

C-Terminal PEGylation Improves SAAP-148 Peptide's Immunomodulatory Activities

Site-Specific PEGylation of Anti-Mesothelin Recombinant Immunotoxins Increases Half-life and Antitumor Activity